Brief: Hyundai Bioscience Develops Injection Drug For Potential Treatment Of Severe Cases Of COVID-19
23/12/2020 04:36
Dec 22 (Reuters) - Hyundai Bioscience Co Ltd 048410.KQ :
* HYUNDAI BIOSCIENCE DEVELOPS INJECTION DRUG FOR POTENTIAL
TREATMENT OF SEVERE CASES OF COVID-19
* HYUNDAI BIOSCIENCE - EXPECTS THAT POLY-COV01 MAY BECOME A
'HOPEFUL SHOT' AS A LAST RESORT FOR SEVERELY ILL PATIENTS WITH
COVID-19
* HYUNDAI BIOSCIENCE - NOW WORKING WITH KOREAN AUTHORITIES
TO
SCHEDULE AN EFFICACY STUDY
Source text for Eikon: ID:nPn28HzbBa
Further company coverage: 048410.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyundai Bioscience Co
See all newsBrief: Hyundai Bioscience Announces Successful Result From Preclinical Study Of Niclosamide-Based Oral Anticancer Drug
S.Korean vaccine firm SK Bioscience sees shares soar 30% on debut (updated)
Vaccine developer SK Bioscience to raise $1.3 bln in S.Korea's largest IPO since 2017 (updated)
Brief: Hyundai Bioscience Develops Injection Drug For Potential Treatment Of Severe Cases Of COVID-19
Brief: Hyundai Bioscience Says Co's COVID-19 Oral Drug Solved Niclosamide's Inhibitory Concentration Problem